However, the impact of this pharmacokinetic interaction between empagliflozin and probenecid has not been studied in patients with T2DM and it is unclear to what extent empagliflozin exposure would increase in the presence of additional OAT3 inhibitors alongside probenecid. This evidence concerns the gene SLC22A8 and type 2 diabetes mellitus.